Cardioprotection by vanadium compounds targeting Akt-mediated signaling

Journal of Pharmacological Sciences

Volumn 110, Issue 1, 2009, Pages 1-13

  Bhuiyan, Md Shenuarin ^a   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Bis(1 oxy 2 pyridinethiolato) oxovanadium (IV) VO(OPT) ; Myocardial hypertrophy; Myocardial ischemia reperfusion; Protein kinase B Akt

Indexed keywords

BIS(1 OXY 2 PYRIDINETHIOLATO)OXOVANADIUM; BIS(MALTOLATO)OXOVANADIUM; GLUCOSE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG; VANADATE SODIUM; VANADIC ACID; VANADIUM DERIVATIVE; VANADYL DERIVATIVE; VANADYL SULFATE;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GLUCOSE TRANSPORT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; VASCULAR DISEASE;

EID: 66349096965     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09R01CR     Document Type: Review

References (137)

1. Almedeida M, Filipe S, Hunianes M, Mala MF, Melo R, Severino N, et al. Vanadium haloperoxidases from brown algae of the Laminariaceae family. Phytochemistry. 2001;57:633-642. (Pubitemid 32568725)
2. Nriagu JP. Vanadium in the Environment, Part 2: Health effects. New York, Chichester, Weinheim, Brisbane, Singapore, Toronto: John Wiley and Sons; 1998.
3. Barceloux DG. Vanadium. J Toxicol Clin Toxicol. 1999;37:265-278.
4. Badmaev V, Prakash S, Majeed M. Vanadium: a review of its potential role in the fight against diabetes. J Altern Complement Med. 1999;5:273-291. (Pubitemid 29282550)
5. Byrne AR, Kosta L. Vanadium in foods and in human body fluids and tissues. Sci Total Environ. 1978;10:17-30. (Pubitemid 8373438)
6. Nechay BR. Mechanisms of action of vanadium. Annu Rev Pharmacol Toxicol. 1984;24:501-524. (Pubitemid 14129545)
7. Nechay BR, Nanninga LB, Nechay PSE, Post RL, Grandham JJ, Macara JG, et al. Role of vanadium in biology. Fed Proc. 1986;45:123-132.
8. French RJ, Jones PJH. Role of vanadium in nutrition: metabolism, essentiality and dietary consideration. Life Sci. 1992;52:339-346.
9. Clarkson PM, Rawson ES. Nutritional supplements to increase muscle mass. Crit Rev Food Sci Nutr. 1999;39:317-328. (Pubitemid 129549614)
10. Kreider RB. Dietary supplements and the promotion of muscle growth with resistance exercise. Sports Medicine. 1999;27:97-110. (Pubitemid 29123581)
11. Fawcett JP, Farquhar SJ, Walker RJ, Thou T, Lowe G, Goulding A. The effect of oral vanadyl sulfate on body composition and performance in weight-training athletes. Int J Sport Nutr. 1996;6:382-390. (Pubitemid 26423482)
12. Ramasarma T, Crane FL. Does vanadium play a role in cellular regulation? Curr Top Cell Regul. 1981;20:247-301.
13. Shechter Y. Insulin-mimetic effects of vanadate: Possible implications for future treatment of diabetes. Diabetes. 1990;39:1-5. (Pubitemid 20022877)
14. Stern A, Yin X, Tsang SS, Davison A, Moon J. Vanadium as a modulator of cellular regulatory cascades and oncogene expression. Biochem Cell Biol. 1993;71:103-112.
15. Geraldes CF, Castro MM, Sherry AD, Ramasamy R. Influence of vanadate on glycolysis, intracellular sodium and pH in perfused rat hearts. Mol Cell Biochem. 1997;170:53-63. (Pubitemid 27182933)
16. Liu H, McNeill JH. Effects of vanadium treatment on the alterations of cardiac glycogen phosphorylase and phosphorylase kinase in streptozotocin- induced chronic diabetic rats. Can J Physiol Pharmacol. 1994;72:1537-1543.
17. Ramanadham S, Brownsey RW, Cros GH, Mongold JJ, McNeill JH. Sustained prevention of myocardial and metabolic abnormalities in diabetic rats following withdrawal from oral vanadyl treatment. Metabolism. 1989;38:1022-1028. (Pubitemid 19255004)
18. Bhuiyan MS, Shibuya M, Shioda N, Moriguchi S, Kasahara J, Iwabuchi Y, et al. Cytoprotective effect of bis(1-oxy-2-pyridinethiolato)oxovanadium (IV) on myocardial ischemia/reperfusion injury elicits inhibition of Fas ligand and Bim expression and elevation of FLIP expression. Eur J Pharmacol. 2007;571:180-188. (Pubitemid 47379683)
19. Bhuiyan MS, Shioda N, Fukunaga K. Targeting protein kinase B/Akt signaling with vanadium compounds for cardioprotection. Expert Opin Ther Targets. 2008;12:1217-1227.
20. Bhanot S, McNeill JH. Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension. 1994;24:625-632. (Pubitemid 24337835)
21. Bhanot S, Bryer-Ash M, Cheung A, McNeill JH. Bis(maltolato)oxovanadium (IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats. Diabetes. 1994;43:857-861. (Pubitemid 24196415)
22. Bhanot S, McNeill JH, Bryer-Ash M. Vanadyl sulfate prevents fructose-induced hyperinsulinemia and hypertension in rats. Hypertension. 1994;23:308-312. (Pubitemid 24076712)
23. Bhanot S, Michoulas A, McNeill JH. Antihypertensive effects of vanadium compounds in hyperinsulinemic, hypertensive rats. Mol Cell Biochem. 1995;153:205-209. (Pubitemid 26003385)
24. Sakurai H, Shimomura S, Fukuzawa K, Ishizu K. Detection of oxovanadium (IV) and characterization of its ligand environment in subcellular fractions of the liver of rats treated with pentavalent vanadium (V). Biochem Biophys Res Commun. 1980;96:293-298.
25. Llobet JM, Domingo JL. Acute toxicity of vanadium compounds in rats and mince. Toxicol Lett. 1984;23:227-231. (Pubitemid 15222129)
26. Sakurai H, Tsuchiya K, Nukatsuka M, Sofue M, Kawada J. Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats. J Endocrinol. 1990;126:241-459. (Pubitemid 20274314)
27. Boscolo P, Carmignani M, Volpe AR, Felaco M, Del Rosso G, Porcelli G, et al. Renal toxicity and arterial hypertension in rats chronically exposed to vanadate. Environ Med. 1994;51:500-503. (Pubitemid 24210989)
28. Bhuiyan MS, Shioda N, Fukunaga K. Activation of eNOS by a vanadium compound ameliorates pressure overload-induced cardiac injury in ovariectomized rats. Hypertension. 2009;53:57-63.
29. Bhuiyan MS, Shioda N, Fukunaga K. Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats. Am J Physiol Endocrinol Metab. 2007;293:E1606-E1614. (Pubitemid 350255110)
30. Bhuiyan MS, Takada Y, Shioda N, Moriguchi S, Kasahara J, Fukunaga K. Cardioprotective effect of vanadyl sulfate on ischemia/reperfusion-induced injury in rat heart in vivo is mediated by activation of protein kinase B and induction of FLICE-inhibitory protein. Cariovasc Ther. 2008;26:10-23.
31. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 2004;37:449-471. (Pubitemid 38953373)
32. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim Biophys Acta. 2004;1697:3-16. (Pubitemid 38326757)
33. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem. 2001;276:38349-38352. (Pubitemid 37371183)
34. Yang ZZ, Tschopp O, Hemmings-Mieszczak M, Feng J, Brodbeck D, Perentes E, et al. Protein kinase B alpha/Akt1 regulates placental development and fetal growth. J Biol Chem. 2003;278:32124-32131. (Pubitemid 37048402)
35. Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest. 2004;113:441-450. (Pubitemid 38544188)
36. Dorn GW 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005;115:527-537.
37. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001;104:330-335. (Pubitemid 32666956)
38. Ou H, Yan L, Mustafi D, Makinen MW, Brady MJ. The vanadyl (VO2+) chelate bis(acetylacetonato)oxovanadium(IV) potentiates tyrosine phosphorylation of the insulin receptor. J Biol Inorg Chem. 2005;10:874-886. (Pubitemid 41682551)
39. Theberge JF, Mehdi MZ, Pandey SK, Srivastava AK. Prolongation of insulin-induced activation of mitogen-activated protein kinases ERK 1/2 and phosphatidylinositol 3-kinase by vanadyl sulfate, a protein tyrosine phosphatase inhibitor. Arch Biochem Biophys. 2003;420:9-17. (Pubitemid 37393369)
40. Mehdi MZ, Srivastava AK. Organo-vanadium compounds are potent activators of the protein kinase B signaling pathway and protein tyrosine phosphorylation: Mechanism of insulinomimetics. Archiv Biochem Biophys. 2005;440:158-164. (Pubitemid 41140380)
41. Reul BA, Amin SS, Buchet JP, Ongemba LN, Crans DC, Brichard SM. Effect of vanadium complexes with organic ligands on glocuse metabolism: a comparison study in diabetic rats. Br J Pharmacol. 1999;126:467-477. (Pubitemid 29057598)
42. Takada Y, Hashimoto M, Kasahara J, Aihara K, Fukunaga K. Cytoprotective effect of sodium orthovanadate on ischemia/reperfusion-induced injury in the rat heart involves Akt activation and inhibition of fodrin breakdown and apoptosis. J Pharmacol Exp Ther. 2004;311:1249-1255. (Pubitemid 39612734)
43. Matsubara T, Musat-Marcu S, Misra HP, Dhalla NS. Protective effect of Vanadate on oxyradical-induced changes in isolated perfused heart. Mol Cell Biochem. 1995;153:79-85. (Pubitemid 26003369)
44. Liem DA, Gho CC, Gho BC, Kazim S, Manintveld OC, Verdouw DD, et al. The tyrosine phosphatase inhibitor bis(maltolato)oxovanadium attenuates myocardial reperfusion injury by opening ATP-sensitive potassium channels. J Pharmacol Exp Ther. 2004;309:1256-1262. (Pubitemid 38669717)
45. Yuen VG, Orvig C, Thompson KH, McNeill JH. Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV). Can J Physiol Pharmacol. 1993;71:270-276. (Pubitemid 23283016)
46. Matsui T, Li L, del Monte F, Fukui Y, Franke T, Hajjar R, et al. Adenoviral gene transfer of activated PI 3-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation. 1999;100:2373-2379.
47. Sakurai H, Sano H, Takino T, Yasui H. An orally active antidiabetic vanadyl complex, bis(1-oxy-2-pyridinethiolato)oxovanadium(IV), with VO(S2O2) coordination mode; in vitro and in vivo evaluations in rats. J Inor Biochem. 2000;80:99-105. (Pubitemid 30628770)
48. Takeshita S, Kawamura I, Yasuno T, Kimura C, Yamamoto T, Seki J, et al. Amelioration of insulin resistance in diabetic ob/ob mice by a new type of orally active insulin-mimetic vanadyl complex: Bis(1-oxy-2-pyridinethiolato) oxovanadium (IV) with VO(S2O2) coordination mode. J Inorg Biochem. 2001;85:179-186. (Pubitemid 32611610)
49. Huyer G, Liu S, Kelly J, Moffat J, Payette P, Kennedy, B, et al. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem. 1997;272:843-851. (Pubitemid 27034572)
50. Swarup G, Cohen S, Garbers DL. Inhibition of membrane phosphotyrosyl-protein phosphatases activity by vanadate. Biochem Biophys Res Commun. 1982;107:1104-1109. (Pubitemid 13207692)
51. Shioda N, Ishigami T, Han F, Moriguchi S, Iwabuchi Y, Fukunaga K. Activation of phosphotidylinositol 3-kinase/protein kinase B pathway by a vanadyl compound mediates its neuroprotective effect in mouse brain ischemia. Neuroscience. 2007;148:221-229. (Pubitemid 47211622)
52. Vijaya S, Crane FL, Ramasarma T. A Vanadate-stimulated NADH oxidase in erythrocyte membrane generates hydrogen peroxide. Mol Cell Biochem. 1984;62:175-185. (Pubitemid 14055589)
53. Cittadini A, Monti MG, Iaccarino G, Di Rella F, Tsichlis PN, Di Gianni A, et al. Adenoviral gene transfer of Akt enhances myocardial contractility and intracellular calcium handling. Gene Therapy. 2006;313:8-19. (Pubitemid 41823847)
54. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367-368. (Pubitemid 40562318)
55. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med. 2003;9:1195-1201. (Pubitemid 37173705)
56. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of Bad couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241. (Pubitemid 27456390)
57. Fukunaga K, Kawano T. Akt is amolecular target for signal transduction therapy in brain ischemia insult. J Pharmacol Sci. 2003;92:317-327. (Pubitemid 37098256)
58. Lizcano JM, Morrice N, Cohen P. Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem J. 2000;349:547-557.
59. Tan Y, Demeter MR, Ruan H, Comb MJ. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem. 2000;275:25865-25869. (Pubitemid 30662039)
60. Masters SC, Yang H, Datta SR, Greenberg ME, Fu H. 14-3-3 inhibits Bad-induced cell death through interaction with serine-136. Mol Pharmacol. 2001;60:1325-1331. (Pubitemid 33144903)
61. Kawano T, Morioka M, Yano S, Hamada J, Ushio Y, Miyamoto E, et al. Decreased Akt activity is associated with activation of Forkhead transcription factor after transient forebrain ischemia in gerbil hippocampus. J Cereb Blood Flow Metab. 2002;22:926-934. (Pubitemid 34831599)
62. Fukunaga K, Ishigami T, Kawano T. Transcriptional regulation of neuronal genes and its effect on neuronal functions: Expression and function of forkhead transcription factors in neurons. J Pharmacol Sci. 2005;98:205-211. (Pubitemid 41296399)
63. Papanicolaou KN, Izumiya Y, Walsh K. Forkhead transcription factors and cardiovascular biology. Circ Res. 2008;102:16-31.
64. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857-868. (Pubitemid 29165088)
65. Dijkers PF, Medema RH, Lammers JWJ, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl02 family member Bim is regulated by the forkhead transcription factor FKHRL-1. Curr Biol. 2000;10:1201-1204.
66. Shioda N, Han F, Moriguchi S, Fukunaga K. Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia. J Neurochem. 2007;102:1506-1517. (Pubitemid 47256193)
67. Kawano T, Fukunaga K, Takeuchi Y, Morioka M, Yano S, Hamada J, et al. Neuroprotective effect of sodium orthovanadate on delayed neuronal death after transient forebrain ischemia in gerbil hippocampus. J Cereb Blood Flow Metab. 2001;21:1268-1280. (Pubitemid 33130939)
68. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein-kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
69. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000;101:660-667. (Pubitemid 30094738)
70. Kemi OJ, Celi M, Wisloff U, Grimaldi S, Gallo P, Smith GL, et al. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J Cell Physiol. 2008;214:316-321. (Pubitemid 350308987)
71. Fulton D, Gratton J-P, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597-601. (Pubitemid 29279181)
72. Fulton D, Gratton J-P, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther. 2001;299:818-824.
73. Papapetropoulos A, Fulton D, Lin MI, Fontana J, McCabe TJ, Zoellner S, et al. Vanadate is a potent activator of endothelial nitric-oxide synthase: evidence for the role of the serine/threonine kinase Akt and the 90-kDa heat shock protein. Mol Pharmacol. 2004;65:407-415. (Pubitemid 38134269)
74. Pabla R, Curtis MJ. Effect of endogenous nitric oxide on cardiac systolic and diastolic function during ischemia and reperfusion in the rat isolated perfused heart. J Mol Cell Cardiol. 1996;28:2111-2121. (Pubitemid 26370958)
75. Schmidt HHHW, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta. 1993;1178:153-175. (Pubitemid 23247995)
76. Shah AM, Silverman HS, Griffiths EJ, Spurgeon HA, Lakatta EG. cGMP prevents delayed relaxation at reoxygenation after brief hypoxia in isolated cardiac myocytes. Am J Physiol Heart Circ Physiol. 1995;268: H2396-H2404.
77. Wu CH, Liu JY, Wu JP, Hsieh YH, Liu CJ, Hwang JM, et al. 17β-Estradiol reduces cardiac hypertrophy mediated through the up-regulation of PI3K/Akt and the suppression of calcineurin/NF-AT3 signaling pathways in rats. Life Sci. 2005;78:347-356. (Pubitemid 41597543)
78. Lu YM, Shioda N, Han F, Moriguchi S, Kasahara J, Shirasaki Y, et al. Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes. Biochem Pharmacol. 2007;74:1727-1737. (Pubitemid 350088677)
79. Ciric O, Susic D. Effect of isoprenaline on blood pressure and heart rate in different phases of the oestrous cycle. Endokrinologie. 1980;76:274-278. (Pubitemid 11180215)
80. Kam KW, Kravtsov GM, Liu J, Wong TM. Increased PKA activity and its influence on isoprenaline-stimulated L-type Ca2+ channels in the heart from ovariectomized rats. Br J Pharmacol. 2005;144: 972-981. (Pubitemid 40593023)
81. Sekar N, Li J, Schechter Y. Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research. Crit Rev Biochem Mol Biol. 1996;31:339-359. (Pubitemid 27024209)
82. Genet S, Kale RK, Baquer NZ. Alterations in antioxidant enzymes and oxidative damage in experimental diabetic rat tissures: effect of vanadate and fenugreek (Trigonella foenum graecum). Mol Cell Biochem. 2002;236:7-12.
83. Shimoni Y, Severson D, Ewart HS. Insulin resistance and the modulation of rat cardiac K(+) currents. Am J Physiol. 2000;279:H639-H649.
84. Takeuchi K, McGowan TX, Glynn P Jr, Moran AM, Rader CM, Cao-Danh H, et al. Glucose transporter upregulation improves ischemic tolerance in hypertrophied failing heart. Circulation. 1998;98:II234-II241. (Pubitemid 28512193)
85. Genet S, Kale RK, Baquer NZ. Effects of vanadate, insulin and fenugreek (Trigonella foenum graecum) on creatine kinase levels in tissues of diabetic rat. Indian J Exp Biol. 1999;37:200-202. (Pubitemid 29103984)
86. Noda C, Masuda T, Sato K, Ikeda K, Shimohama T, Matsuyama N, et al. Vanadate improves cardiac function and myocardial energy metabolism in diabetic rat hearts. Jpn Heart J. 2002;44:745-757.
87. Donthi RU, Huisamen H, Lochner A. Effect of vanadate and insulin on glucose transport in isolated adult rat cardiomyocytes. Cardiovasc Drugs Ther. 2000;14:463-470.
88. Kopp SJ, Daar J, Paulson DJ, Romano FD, Laddaga R. Effects of oral vanadyl treatment on diabetes-induced alterations in the heart GLUT-4 transporter. J Mol Cell Cardiol. 1997;29:2355-2362. (Pubitemid 27404428)
89. Li SH, McNeill JH. In vivo effects of vanadium of GLUT-4 translocation in cardiac tissue of STZ-diabetic rats. Mol Cell Biochem. 2001;212:121-129.
90. Garvey WT, Hardin D, Juhaszova M, Dominguez JH. Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy. Am J Physiol. 1993;264:H837-H844. (Pubitemid 23109876)
91. Mohammad A, Sharma V, McNeill JH. Vanadium increases GLUT4 in diabetic rat skeletal muscle. Mol Cell Biochem. 2002;233:139-143. (Pubitemid 34746120)
92. Huisamen B, Donthi RV, Lochner A. Insulin in combination with vanadate stimulates glucose transport in isolated cardiomyocytes from obese Zucker rats. Cardiovasc Drugs Ther. 2001;15:445-452. (Pubitemid 34098515)
93. Tardif A, Julien J, Chiasson JL, Coderre L. Stimulation of glucose uptake by chronic vanadate pretreatment in cardiomyocytes requires PI 3-kinase and p38 MAPK activation. Am J Physiol. 2003;284:E1055-E1064. (Pubitemid 36617449)
94. Huisamen B. Protein kinase B in the diabetic heart. Mol Cell Biochem. 2003;249:31-38. (Pubitemid 37021026)
95. Molero JC, Perez C, Martinez C, Villar M, Andres A, Fermin Y, et al. Activation of MAP kinase by insulin and vanadate in adipocytes from young and old rats. Mol Cell Endocrinol. 2002;189:77-84. (Pubitemid 34229165)
96. Ozaki H, Urakawa N. Effects of vanadate on mechanical responses and Na-K pump in vascular smooth muscle. Eur J Pharmacol. 1980;68:339-347. (Pubitemid 11195696)
97. Nayler RA, Sparrow MP. Mechanism of vanadate-induced contraction of airways smooth muscle of the guinea-pig. Br J Pharmacol. 1983;80:163-172.
98. Shimada T, Shimamura K, Sunano S. Effects of sodium vanadate on various types of vascular smooth muscles. Blood Vessels. 1986;23:113-124. (Pubitemid 16099427)
99. Sandirasegarane L, Gopalakrishnan V. Vanadate increases cytosolic free calcium in rat aortic smooth muscle cells. Life Sci. 1995;56:PL169-PL174.
100. Tamura S, Brown TA, Whipple JH, Fujita-Yamaguchi Y, Dubler RE, Cheng K, et al. A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes. J Biol Chem. 1984;259:6650-6658. (Pubitemid 14108223)
101. Di Salvo J, Semenchuk LA, Lauer J. Vanadate-induced contraction of smooth muscle and enhanced protein tyrosine phosphorylation. Arch Biochem Biophys. 1993;304:386-391. (Pubitemid 23232952)
102. Laniyonu A, Saifeddine M, Ahmed S, Hollenberg MD. Regulation of vascular and gastric smooth muscle contractility by pervanadate. Br J Pharmacol. 1994;113:403-410. (Pubitemid 24310735)
103. Carr AN, Davis MG, Eby-Wilkens E, Howard BW, Towne BA, Dufresne TE, et al. Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease. Am J Physiol Heart Circ Physiol. 2004;287:H268-H276. (Pubitemid 38802362)
104. Shah DI, Singh M. Inhibition of protein tyrosine phosphatase improves vascular endothelial dysfunction. Vasc Pharmacol. 2006;44:177-182. (Pubitemid 43183666)
105. Shah DI, Singh M. Effect of bis(maltolato)oxovanadium on experimental vascular endothelial dysfunction. Naunyn Schmiedebergs Arch Pharmacol. 2006;373:221-229. (Pubitemid 43829496)
106. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 1996;94:1074-1082. (Pubitemid 26292864)
107. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994;93:662-670. (Pubitemid 24983202)
108. Shyu KG, Manor O, Magner M, Yancopoulos GD, Isner JM. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation. 1998;98:2081-2087. (Pubitemid 28512235)
109. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 2003;9:604-613. (Pubitemid 36597108)
110. Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nat Biotechnol. 2001;19:1029-1034. (Pubitemid 33041886)
111. Srivastava AK. Anti-diabetic and toxic effects of vanadium compounds. Mol Cell Biochem. 2000;206:177-182.
112. Srivastava AK, Mehdi MZ. Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabet Med. 2005;22:2-13.
113. Strout HV, Vicario PP, Saperstein R, Slater EE. The insulin-mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity or phosphorylation in mouse diaphragm in vivo. Endocrinology. 1989;124:1918-1924. (Pubitemid 19105465)
114. Meyerovitch J, Farfel Z, Sack J, Shechter Y. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats: Characterization and mode of action. J Biol Chem. 1987;262:6658-6662. (Pubitemid 17104143)
115. Domingo JL, Gomez M, Sanchez DJ, Llobet JM, Keen CL. Toxicology of vanadium compounds in diabetic rats: the action of chelating agents on vanadium accumulation. Mol Cell Biochem. 1995;153:233-240. (Pubitemid 26004034)
116. Domingo JL. Vanadium and tungsten derivatives as antidiabetic agents: a review of their toxic effects. Biol Trace Elem Res. 2002;88:97-112.
117. Faure R, Vincent M, Dufour M, Shaver A, Posner BI. Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: studies on a neuronal and a glial cell line. J Cell Biochem. 1995;59:389-401.
118. Fantus IG, Tsiani E. Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Mol Cell Biochem. 1998;182:109-119. (Pubitemid 28181654)
119. Djordjevic C. Antitumor activity of vanadium compounds. Met Ions Biol Syst. 1995;31:595-616.
120. Liasko R, Kabanos TA, Karkabounas S, Malamas M, Tasiopoulos AJ, Stefanou D, et al. Beneficial effects of a vanadium complex with cysteine, administered at low doses on benzo (alpha) pyrene-induced leiomyosarcomas in Wistar rats. Anticancer Res. 1998;18:3609-3613. (Pubitemid 28546498)
121. Blondel O, Bailbe D, Portha B. In vivo insulin resistance in streptozotocin diabetic rats - evidence for reversal following oral vanadate treatment. Diabetologia. 1989;32:185-190.
122. Al-Bayati MA, Giri SN, Raah OG. Time and dose response study of the effects of vanadate in rats: changes in blood cells, serum enzymes, protein, cholesterol, glucose, calcium and inorganic phosphate. J Environ Pathol Toxicol Oncol. 1990;10:206-213.
123. Bishayee A, Cecchin F. Time course effects of vanadium supplements on cytosolic reduced glutathione level and glutathione S-transferase activity. Biol Trace Element Res. 1995;48:275-285.
124. Mongold JJ, Cros GH, Vian L, Tep A, Ramanadham S, Siou G, et al. Toxicological aspects of vanadyl sulphate on diabetic rats: effects on vanadium levels and pancreatic B-cell morphology. Pharmacol Toxicol. 1990;67:192-198. (Pubitemid 20352099)
125. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem. 1995;153:217-231.
126. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;95:2501-2509.
127. Reiss K, Cheng W, Ferber A, Kajsture J, Li P, Li B, et al. Overexpression of insulin-like grwoth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci U S A. 1996;93:8630-8635. (Pubitemid 26269611)
128. Gude N, Muraski J, Rubio M, Kajstura J, Schaefer E, Anversa P, et al. Akt promotes increased cardiomyocyte cycling and expansion of the cardiac progenitor cell population. Circ Res. 2006;99:381-388. (Pubitemid 44253694)
129. DeBosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, Coutrois M, et al. Akt 1 is required for physiological heart growth. Circulation. 2006;113:2097-2104. (Pubitemid 43755160)
130. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, et al. Phosphoinositide 3-kinase (p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A. 2003;100:12355-12360. (Pubitemid 37271564)
131. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114:763-776. (Pubitemid 37186770)
132. Urbanek K, Quaini F, Tasca G, Torella D, Castaldo C, Nadal- Ginard B, et al. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc Natl Acad Sci U S A. 2003;100:10440-10445. (Pubitemid 37071897)
133. Matsumoto J, Morioka M, Hasegawa Y, Kawano T, Yoshinaga Y, Maeda T, et al. Sodium orthovanadate enhances proliferation of progenitor cells in the adult rat subventricular zone after focal cerebral ischemia. J Pharmacol Exp Ther. 2006;318:982-991. (Pubitemid 44268303)
134. Shioda N, Han F, Morioka M, Fukunaga K. Bis(1-oxy-2-pyridinethiolato) oxovanadium (IV) enhances neurogenesis via phosphatidylinositol 3-kinase/Akt and extracellular signal regulated kinase activation in the hippocampal subgranular zone after mouse focal cerebral ischemia. Neuroscience. 2008;155:876-887.
135. Duan J, Zhang HY, Adkins SD, Ren BH, Norby FL, Zhang X, et al. Impaired cardiac function and IGF-I response in myocytes from calmodulin-diabetic mice: role of Akt and RhoA. Am J Physiol Endocrinol Metab. 2003;284:E366-E376. (Pubitemid 36120110)
136. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 2001;103:670-677. (Pubitemid 32144195)
137. Taniyama Y, Walsh K. Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. J Moll Cell Cardiol. 2002;34:1241-1247. (Pubitemid 35244397)